Recent News: Cancer Immunotherapy & Vaccines

and/or

25 News Items found

Finding

Tumor Mutational Burden Can Help Predict Response to Immunotherapy in Many Different Cancers

Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.

Tumor mutation model

In the Lab

Drugs That Stall — But Don’t Kill — Cancer Cells Are an Untapped Resource, Study Suggests

A drug combination that halts tumor cell division can stir the immune system into taking action.

electron micrograph of a natural killer cell

In the Lab

MSK Scientists Fine-Tune CAR T Cells to Improve Their Performance

The updated versions can survive longer in the body while still packing a punch against cancer.

Illustration of mechanical arms altering a cell

In the Lab

The Immune System Can Fight Cancer. So Why Doesn’t It?

New research from scientists at the Sloan Kettering Institute helps explain how growing tumors escape our immune defenses.

a cabinet full of yellow rubber duckies and one blue one

Finding

Adding Low-Dose Radiation Could Make CAR T Therapy More Effective, Study Finds

The treatment combination appears to boost chimeric antigen receptor (CAR) T cells’ ability to kill cancer cells in solid tumors.

Blue cancer cell with a target on it

In the News

Former MSK Immunologist James Allison Wins Nobel Prize in Medicine

Dr. Allison is being honored for discovering how to take the brakes off cancer-fighting immune cells.

James Allison

Finding

Discovery of Unusual Cell Type Could Help Guide Immunotherapy

A newly identified group of immunosuppressive cells could provide insight into the effects of immunotherapy drugs.

Scanning electron micrograph (SEM) of T lymphocyte cells (blue) attached to a red cancer cell.

In the Lab

Why Do Immune Checkpoint Inhibitors Work for Only Some People with Cancer?

Learn about why checkpoint inhibitors, a class of immunotherapy drugs, 
is paying off — but only for some patients.

MSK physician­scientist Luis Diaz

In the Clinic

The Science Behind the FDA’s Approval of an Immunotherapy for Mismatch Repair–Deficient Cancers

A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.

MSK medical oncologist Luis Diaz, Jr.